317 related articles for article (PubMed ID: 25140557)
1. Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone.
Sampath SC; Sampath SC; Mosci C; Lutz AM; Willmann JK; Mittra ES; Gambhir SS; Iagaru A
Clin Nucl Med; 2015 Mar; 40(3):e173-7. PubMed ID: 25140557
[TBL] [Abstract][Full Text] [Related]
2. Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients.
Jackson T; Mosci C; von Eyben R; Mittra E; Ganjoo K; Biswal S; Gambhir SS; Iagaru A
Clin Nucl Med; 2015 Sep; 40(9):720-4. PubMed ID: 26053718
[TBL] [Abstract][Full Text] [Related]
3. Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy.
Lin FI; Rao JE; Mittra ES; Nallapareddy K; Chengapa A; Dick DW; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):262-70. PubMed ID: 22065013
[TBL] [Abstract][Full Text] [Related]
4. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
[TBL] [Abstract][Full Text] [Related]
5. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.
Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Gross ME; Pinski JK; Quinn DI
Clin Nucl Med; 2012 Jul; 37(7):637-43. PubMed ID: 22691503
[TBL] [Abstract][Full Text] [Related]
7. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
[TBL] [Abstract][Full Text] [Related]
9. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
10. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.
Simoncic U; Perlman S; Liu G; Jeraj R
Nucl Med Commun; 2015 Dec; 36(12):1174-80. PubMed ID: 26378490
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
Iagaru A; Mittra E; Dick DW; Gambhir SS
Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
13. Comparison of
Zhang Y; Chen Y; Huang Z; Zhang L; Wan Q; Lei L
Contrast Media Mol Imaging; 2018; 2018():8271313. PubMed ID: 30254551
[TBL] [Abstract][Full Text] [Related]
14. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
Ak İ; Onner H; Akay OM
Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066
[TBL] [Abstract][Full Text] [Related]
15. Utility of 18F-fluorodeoxy glucose and 18F-sodium fluoride positron emission tomography/computed tomography in the diagnosis of medication-related osteonecrosis of the jaw: A preclinical study in a rat model.
Kim Y; Lee HY; Yoon HJ; Kim BS
J Craniomaxillofac Surg; 2016 Apr; 44(4):357-63. PubMed ID: 26880011
[TBL] [Abstract][Full Text] [Related]
16. Different lesions revealed by 18F-FDG PET/CT and 18F-NaF PET/CT in patients with multiple myeloma.
Xu F; Liu F; Pastakia B
Clin Nucl Med; 2014 Sep; 39(9):e407-9. PubMed ID: 24217536
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using
Nakuz TS; Millinger FP; El-Rabadi K; Weber M; Pichler V; Wadsak W; Mitterhauser M; Haug A; Hacker M; Karanikas G; Pietschmann P; Agis H
Anticancer Res; 2019 Apr; 39(4):1943-1952. PubMed ID: 30952737
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis.
Liu NB; Zhu L; Li MH; Sun XR; Hu M; Huo ZW; Xu WG; Yu JM
Asian Pac J Cancer Prev; 2013; 14(6):3647-52. PubMed ID: 23886160
[TBL] [Abstract][Full Text] [Related]
19. [Superiority of 18F-FNa PET/CT for Detecting Bone Metastases in Comparison with Other Diagnostic Imaging Modalities].
Lapa P; Saraiva T; Silva R; Marques M; Costa G; Lima JP
Acta Med Port; 2017 Jan; 30(1):53-60. PubMed ID: 28501038
[TBL] [Abstract][Full Text] [Related]
20. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]